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A B S T R A C T
Objective. To evaluate the impact of antioxidant therapy on functional health status in Fontan-palliated patients.
Design. Prospective, randomized, double-blind, placebo-controlled trial.
Patients. Fifty-three generally asymptomatic Fontan patients.
Interventions. Patients were randomized to receive either high-dose ascorbic acid (vitaminC) or placebo for 4 weeks.
Outcome Measures. Peripheral vascular function, as measured with endothelium-dependent digital pulse amplitude
testing (EndoPAT), and exercise capacity were assessed before and after study drug treatment. Primary outcome
measures included the EndoPAT index and peripheral arterial tonometry (PAT) ratio, both validated markers of
vascular function. Secondary outcome measures included peak oxygen consumption and work.
Results. Twenty-three vitamin C- and 21 placebo-assigned subjects completed the protocol (83%). Median age and
time from Fontan completion were 15 (interquartile range [IQR] 11.7–18.2) and 11.9 years (IQR 9.0–15.7),
respectively. Right ventricular morphology was dominant in 30 (57%). Outcome measures were similar between
groups at baseline. Among all subjects, vitamin C therapy was not associated with a statistical improvement in either
primary or secondary outcome measures. In subjects with abnormal vascular function at baseline, compared with
placebo, vitamin C therapy more frequently resulted in normalization of the EndoPAT index (45% vs. 17%) and
PAT ratio (38% vs. 13%).
Conclusions. Short-term therapy with vitamin C does not alter endothelial function or exercise capacity in an
asymptomatic Fontan population overall. Vitamin C may provide beneﬁt to a subset of Fontan patients with
abnormal vascular function.
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Introduction
Following Fontan palliation in patients withsingle ventricle lesions, early development of
ventricular dysfunction and heart failure is com-
mon.1,2 Endothelial dysfunction, a well-described
risk factor for congestive heart failure and future
cardiovascular events in adults, has been identiﬁed
as problematic in some Fontan populations.3–7
This is important because abnormalities in vascu-
lar function have been correlated with diminished
functional health status, including impaired exer-
cise capacity.6,7 Recently, interest has developed in
utilizing therapies directed—in part—at improv-
ing endothelial function as a means to improve
functional status. To date, therapies trialed includ-
ing angiotensin-converting enzyme inhibitors,
phosphodiesterase type 5 inhibitors, and aldoster-
one antagonists have had limited efﬁcacy in the
Fontan population.8–10
Endothelial dysfunction may be due to reduced
synthesis of nitric oxide (NO) by NO synthases,
reduced availability of L-arginine (the amino acid
substrate for NO production), or enhanced inac-
tivation of NO by free radicals. Mahle and col-
leagues provided evidence for increased levels of
oxygen-derived free radicals—NO scavengers—in
Fontan patients with reduced endothelial func-
tion.4 Antioxidants such as ascorbic acid (vitamin
Clinical trials registration: ClinicalTrials.gov
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C) have been shown to prevent NO inactivation
and preserve endothelium-dependent vasodila-
tion.11,12 Vitamin C improves endothelial function
in patients with systemic hypertension and with
chronic heart failure.13,14 However, it is not known
whether antioxidants such as vitamin C would be
beneﬁcial for patients with single ventricle physi-
ology following Fontan palliation. In the present
study, we sought to evaluate the impact of vitamin
C on peripheral vascular function and exercise
capacity in patients with a Fontan circulation, after
short-term oral therapy.
Methods
This prospective study was approved by the Uni-
versity of Michigan Institutional Review Board.
Fontan subjects ages 8–25 years were identiﬁed by
search of the institutional pediatric cardiothoracic
surgical database and approached for study partici-
pation. To reduce risk to participants and reduce
the impact of confounding variables, we excluded
Fontan subjects with pacemaker dependence,
severe hypoxemia (oxygen saturation <80% at
rest), atrial arrhythmia requiring treatment in the
past 6 months, active protein losing enteropathy,
prior life-threatening ventricular arrhythmia or
cardiac arrest outside of the immediate peri-
operative period, severe ventricular dysfunction or
atrioventricular valve insufﬁciency, medically
uncontrolled heart failure, systemic or pulmonary
artery hypertension requiring therapy, or moder-
ate to severe asthma. All subjects or parents gave
informed consent, and minors gave assent, prior to
enrolling in the study.
Baseline serum brain natriuretic peptide
(BNP) was obtained. Endothelium-dependent
digital pulse amplitude testing (EndoPAT) was
performed in a quiet, darkened, temperature-
controlled room (maintained between 72 and
75°F). Subjects were asked to fast, except for the
consumption of water, for 4 hours prior to
testing and to avoid the use of caffeine or tobacco
for 12 hours prior to testing. No modiﬁcations to
routine cardiac medication dosing were advised.
The testing protocol was carried out using the
EndoPAT2000 device as instructed by the
company (Itamar Medical Ltd, Caesarea, Israel)
and previously described by our group and oth-
ers.7,15 Brieﬂy, digital pulse amplitude was
recorded electronically in both index ﬁngers
throughout the testing period, from baseline
through 3 minutes after induction of reactive
hyperemia by 5-minute cuff occlusion of one
arm. An automated algorithm generated the
mean pulse amplitude for each 30-second interval
during the reactive hyperemia phase of reperfu-
sion. Baseline pulse amplitude, a measure that
reﬂects resting arterial tone, was deﬁned as the
mean pulse amplitude obtained during the 2
minutes and 20 seconds immediately preceding
the interruption of arterial inﬂow with cuff inﬂa-
tion. EndoPAT index, a measure of hyperemic
response adjusted for baseline blood ﬂow, was
deﬁned as the ratio of the average pulse ampli-
tude (during the 1 minute period beginning after
90 seconds of reactive hyperemia) divided by the
average baseline pulse amplitude.16 The periph-
eral arterial tonometry (PAT) ratio was deter-
mined using the previously validated natural
logarithmic transformation of the ratios of peak
hyperemic digit pulse amplitude and control digit
pulse amplitude, each corrected for baseline pulse
amplitude.17 PAT ratio has been demonstrated to
better correlate with traditional cardiovascular
risk factors in adults than do other measures
obtained with EndoPAT testing.17
Cardiopulmonary exercise testing was per-
formed immediately following EndoPAT testing.
Treadmill exercise testing utilized the 3-minute
incremental exercise protocol described by Bruce
et al.18 Electrocardiographic monitoring and
breath-by-breath expiratory gas analysis were per-
formed with a Medical Graphics exercise testing
system (Medical Graphics Corporation, St. Paul,
MN, USA). Subjects were encouraged to exercise
to the point of exhaustion. Peak oxygen con-
sumption (VO2) was deﬁned as the highest VO2
recorded during the test. The oxygen pulse was
calculated by dividing the peak VO2 by the peak
heart rate. Ventilatory anaerobic threshold was
calculated using the V-slope method when it could
be accurately determined.19 Subjects had heart
rate, blood pressure, and oxygen saturation moni-
tored serially throughout the study. The study was
terminated when the subject reached exhaustion
or experienced signiﬁcant symptoms. Testing was
supervised by an exercise technologist overseen by
a pediatric cardiologist. Predicted values were cal-
culated using age- and sex-speciﬁc normative data
previously established for the Bruce protocol.
Subjects were randomized to oral vitamin C or
placebo. Vitamin C dosing was standardized for
age, based upon published tolerable upper intake
levels: age 8—500 mg, ages 9–13—1000 mg, ages
14–18—1500 mg, age >18—2000 mg.20 After 4
weeks of therapy, subjects returned for repeat
assessment of BNP, EndoPAT, and cardiopulmo-
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nary exercise testing. Vitamin C therapy was dis-
continued at study completion, unless continued
at the discretion of the individual patient or his/
her primary cardiologist.
Group comparisons were made on the basis of
the intent-to-treat principle. Baseline characteris-
tics were compared by using t-tests or Wilcoxon
rank sum tests for continuous variables, and chi-
square tests or Fisher’s exact tests for nominal
variables. Analysis of covariance adjusting for base-
line values was conducted to examine the treatment
effects (vitaminC vs. placebo) on changes in endot-
helial function and exercise testing from baseline to
follow-up testing. All analyses were performed
using SAS Version 9.2 (SAS Institute Inc, Cary,
NC, USA), with statistical signiﬁcance set at P
values 0.05 using two-sided tests.
Results
Demographics
The 53 Fontan-palliated subjects who enrolled in
the study were randomized to vitamin C (n = 27)
or placebo (n = 26). Baseline testing was com-
pleted by all subjects. During the protocol, follow-
ing randomization and prior to completion of
follow-up testing, nine patients (four in the
vitamin C arm and ﬁve in the placebo arm) exited
the study. Demographic and medical characteris-
tics of the study population are displayed in
Table 1. Baseline characteristics were similar
between groups except for a family history of dia-
betes mellitus, which was more common in the
placebo arm. Nearly two-thirds of the cohort
was male, and 90% were white. Hypoplastic left
heart syndrome was the most common anatomic
diagnosis (47%), and 57% had a systemic right
ventricle. Patients were generally clinically
asymptomatic with 94% being New York Heart
Association functional class I and the median
serum BNP level measuring 18 pg/mL.
Endothelial Function
The results of endothelial function testing are
summarized in Table 2. Resting pretreatment
heart rate and systolic and diastolic blood pres-
sures were normal. Vitamin C had no meaningful
effect on these resting parameters. Markers of
endothelial function acquired with PAT testing
were similar between vitamin C and placebo
groups at baseline. When compared with data
previously acquired from healthy controls, the
Fontan patients at baseline demonstrated evi-
dence of reduced basal peripheral arterial tone
and vasodilator response, suggesting dysfunction
of the endothelium-derived NO pathway.7 After
1 month of study drug treatment, baseline pulse
amplitude—a marker of resting peripheral arte-
Table 1. Demographic and Medical Characteristics of the Study Population
Characteristic
Vitamin C Placebo
P(n = 27) (n = 26)
Male sex 16 (59%) 17 (65%) 0.65
Caucasian race 25 (93%) 23 (89%) 0.67
Age (years) 13.9 (9.6–18.2) 15.7 (12.2–18.7) 0.56
Weight (kg) 51.9 (19.2) 52.9 (17.8) 0.85
Height (cm) 155.1 (19.6) 159.5 (17.2) 0.38
BMI (kg/m2) 20.8 (4.7) 20.3 (4.5) 0.68
BSA (m2) 1.5 (0.4) 1.5 (0.3) 0.65
Age at Fontan (years) 2.1 (1.6–2.8) 2.2 (1.9–3) 0.10
Ventricular morphology 0.21
Single right ventricle 13 (48%) 17 (65%)
Single left ventricle 14 (52%) 9 (35%)
Patent fenestration 7 (26%) 6 (23%) 0.62
NYHA class I 26 (96%) 24 (92%) 0.61
Serum BNP (pg/mL) 20.5 (15.5–35.5) 19.5 (18–37) 0.67
ACE inhibitor use 9 (33%) 13 (50%) 0.22
Multivitamin 9 (33%) 9 (35%) 0.92
Tobacco exposure 4 (15%) 3 (12%) 1.0
FHx coronary disease 8 (30%) 10 (39%) 0.50
FHx diabetes 7 (26%) 16 (62%) 0.01
FHx hypertension 15 (56%) 14 (54%) 0.90
FHx hyperlipidemia 14 (52%) 14 (54%) 0.88
FHx stroke 8 (30%) 10 (39%) 0.50
Values are median (interquartile range [IQR]) or mean (standard deviation [SD]) for continuous variables and number (%) for categorical variables.
ACE, angiotensin converting enzyme; BMI, body mass index; BNP, brain natriuretic peptide; BSA, body surface area; FHx, family history of disease; NYHA, New
York Heart Association.
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rial tone—was not changed signiﬁcantly between
the two groups. There were no signiﬁcant
changes to the EndoPAT index or the PAT ratio
associated with vitamin C therapy. We performed
a post hoc subgroup analysis of study subjects
with abnormal baseline markers of peripheral
vascular function (which we deﬁned as a value
below the 25th percentile for healthy controls) to
evaluate for normalization of vascular function
(deﬁned as improvement to 25th percentile for
healthy controls).7 Among subjects with evidence
of endothelial dysfunction at baseline, a non-
signiﬁcantly greater percentage of vitamin
C-treated individuals demonstrated normaliza-
tion of the EndoPAT index (45 vs. 17%, P =
0.33; Figure 1) and PAT ratio (38 vs. 13%, P =
0.34; Figure 2), compared with placebo-treated
subjects.
Exercise Capacity
The study groups demonstrated similar exercise
parameters at rest, anaerobic threshold, and peak
exercise during baseline cardiopulmonary exercise
testing, as presented in Table 3. Treatment with
high-dose vitamin C was not associated with
statistically signiﬁcant changes in any key para-
meter of exercise capacity, including peak VO2
(Figure 3), work, or oxygen pulse. Notably, the
exercise performance of the study population was
quite good, compared with existing Fontan exer-
Table 2. Endothelial Function at Baseline and after 1 Month of Therapy
Parameter
Vitamin C (n = 23) Placebo (n = 21)
Treatment Effect* PBaseline Follow-up Baseline Follow-up
Heart rate (bpm) 74.4 (11.4) 77.0 (10.2) 73.5 (11.9) 72.6 (11.6) 3.1 (-0.3–6.6) 0.08
Systolic blood pressure (mm Hg) 109.3 (13.2) 105.7 (15.2) 108.3 (13.5) 108.6 (9.6) -3.5 (-10.3–3.4) 0.31
Diastolic blood pressure (mm Hg) 70.9 (8.5) 69.0 (11.7) 69.0 (7.4) 70.0 (7.3) -1.7 (-7.7–4.3) 0.57
Baseline pulse amplitude 3.48 (1.79) 3.25 (2.34) 3.34 (2.54) 3.68 (2.58) -0.52 (-2.02–0.97) 0.48
EndoPAT index 1.39 (0.42) 1.47 (0.47) 1.47 (0.31) 1.49 (0.33) 0.04 (-0.22–0.30) 0.76
PAT ratio 0.15 (0.33) 0.22 (0.35) 0.26 (0.31) 0.30 (0.26) 0.01 (-0.18–0.19) 0.93
Values are mean (SD). There were no differences between groups at baseline (all P > 0.05).
*Treatment effect is defined as the change from baseline in the vitamin C group minus the change from baseline in the placebo group and presented as least
squares means difference (95% confidence intervals) and P from analysis of covariance.
Figure 1. Change in EndoPAT index among subjects with significant endothelial dysfunction. Individual measurements
(filled circles) of EndoPAT index at baseline and following 1 month of study drug therapy in 11 vitamin C (A) and 6 placebo
(B) patients with abnormal EndoPAT index at baseline. Patients who demonstrated a response in EndoPAT index to 25th
percentile of normal are denoted in dashed-dot black lines, while patients without a significant response are denoted in solid
gray lines. The dashed horizontal lines represent the 25th percentile EndoPAT index achieved in healthy controls, while the
solid black lines represent the mean EndoPAT index measured in each group. Normalization of EndoPAT index occurred in
5 of 11 (45%) vitamin C subjects (P = 0.04) and 1 of 6 (17%) placebo subjects (P = 0.84) with abnormal EndoPAT index at
baseline.
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cise datasets in the literature, as assessed by peak
VO2 and peak work achieved.21
Side Effects and Compliance
Compliance with study drug administration could
be assessed in 39 (89%) of the 44 subjects who
completed the study protocol. Overall, medication
compliance (deﬁned as use of 80% of expected
medication volume) was more common in the
vitamin C group (95 vs. 74%), although this differ-
ence was not statistically signiﬁcant. Subgroup
analysis of compliant patients did not yield differ-
ent results from the overall intent-to-treat analysis,
with respect to the key vascular function and exer-
cise end points. Adverse events possibly or probably
related to study drug exposure are detailed in
Table 4. The only hospitalization of a study patient
during the study period was deemed unrelated to
Figure 2. Change in PAT ratio among subjects with significant endothelial dysfunction. Individual measurements (filled
circles) of PAT ratio at baseline and following 1 month of study drug therapy in 13 vitamin C (A) and eight placebo (B) patients
with abnormal PAT ratio at baseline. Patients who demonstrated a response in PAT ratio to 25th percentile of normal are
denoted in in dashed-dot black lines, while patients without a significant response are denoted in solid gray lines. The dashed
horizontal lines represent the 25th percentile PAT ratio achieved in healthy controls, while the solid black lines represent the
mean PAT ratio measured in each group. Normalization of PAT ratio occurred in 5 of 13 (38%) vitamin C subjects (P = 0.04)
and 1 of 8 (13%) placebo subjects (P = 0.84) with abnormal PAT ratio at baseline.
Table 3. Exercise Performance at Baseline and after 1 Month of Therapy
Parameter
Vitamin C (n = 23) Placebo (n = 21)
Treatment Effect* PBaseline Follow-up Baseline Follow-up
Rest
Oxygen saturation (%) 92.2 (3.1) 92.4 (3.1) 91.8 (5.4) 91.5 (4.5) 0.4 (-1.0–1.9) 0.55
Respiratory rate (bpm) 21.4 (6.4) 19.8 (4.5) 21.7 (6.0) 20.7 (5.3) -0.5 (-3.5–2.6) 0.76
Anaerobic threshold
Oxygen consumption (mL/kg/min) 17.6 (4.1) 17.3 (3.6) 17.5 (3.5) 16.8 (3.6) 0.2 (-1.4–1.8) 0.80
Work (W) 91.3 (37.7) 92.6 (44.3) 89.9 (47.2) 96.9 (34.5) 5.5 (-16.7–27.7) 0.62
Minute ventilation (L/min) 26.5 (7.4) 24.9 (8.7) 25.8 (8.1) 26.0 (7.9) 1.2 (-2.4–4.9) 0.49
Peak exercise
Oxygen consumption (mL/kg/min) 30.1 (8.1) 30.6 (7.8) 29.4 (6.5) 29.8 (7.0) 0.7 (-2.2–3.6) 0.64
Oxygen consumption (% predicted) 71.9 (15.4) 71.2 (16.5) 68.9 (14.8) 68.1 (16.7) 2.2 (-5.0–9.5) 0.53
Oxygen pulse (mL/beat/BSA) 6.6 (1.7) 6.7 (1.6) 6.4 (1.0) 6.8 (1.0) -0.1 (-0.7–0.5) 0.81
Work (W) 194.0 (76.2) 205.7 (104.5) 199.8 (77.3) 228.4 (80.0) 7.5 (-20.4–35.5) 0.59
Heart rate (bpm) 152.1 (22.7) 153.1 (18.4) 153.7 (17.6) 148.1 (18.1) 4.7 (-5.0–14.4) 0.33
Oxygen saturation (%) 88.4 (3.9) 89.3 (3.7) 88.4 (7.2) 87.4 (8.0) 0.5 (-1.3–2.3) 0.59
Respiratory exchange ratio 1.03 (0.07) 1.00 (0.09) 1.02 (0.08) 1.01 (0.07) -0.01 (-0.1–0.04) 0.69
Respiratory rate (bpm) 50.0 (11.7) 49.7 (11.6) 44.4 (6.2) 44.3 (6.6) 2.3 (-2.8–7.5) 0.37
Minute ventilation (L/min) 54.0 (23.5) 55.1 (23.8) 51.9 (17.0) 54.4 (15.3) 2.2 (-4.1–8.6) 0.48
Values are mean (SD). There were no differences between groups at baseline (all P > 0.05).
*Treatment effect is defined as the change from baseline in the vitamin C group minus the change from baseline in the placebo group and presented as least
squares means difference (95% confidence intervals) and P from analysis of covariance.
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the protocol (pacemaker malfunction due to lead
dysfunction). Overall, side effects were more com-
monly reported in the placebo group (19 vs. 11%).
Discussion
In the present randomized, double-blind, placebo-
controlled study of oral vitamin C therapy in
Fontan-palliated patients, we found that vascular
function and exercise capacity were not improved
in response to antioxidant treatment, in the cohort
overall. The primary outcome measures, Endo-
PAT index and PAT ratio—both validated
measures of endothelial function—were not sig-
niﬁcantly different after 1 month of therapy with
vitamin C.17 The key secondary outcome mea-
sures, VO2 and work at peak exercise, were not
signiﬁcantly different in the vitamin C cohort.
Exercise function in the cohort overall was com-
parable to recent, large, prospective studies in the
Fontan population.7,9,21
Antioxidant Therapy in Heart Disease
The use of antioxidant therapy in heart disease is
well established. A number of antioxidants have
been demonstrated to be protective against cardio-
vascular mortality, stroke, and congestive heart
failure, including vitamins C, E, and others.22–24
The dysfunctional vascular endothelium has
been identiﬁed as a primary target for antioxidant
therapies in these disease states.25 Vitamin C, spe-
ciﬁcally, has been demonstrated to improve
endothelial function in patients with essential
hypertension and in chronic heart failure.13,14,25,26
Our group and others have shown that endothelial
dysfunction is common in the Fontan population
and is associated with a reduced functional health
status.3,6,7 Thus, there is good biological plausibility
for utilizing oral vitamin C, a low-cost, readily
available antioxidant with minimal side effect
proﬁle, in the treatment of endothelial dysfunction
in Fontan-palliated functional single-ventricle
patients.
Endothelial Function and Functional Status
To be effective in improving functional health
status, a therapy directed at bettering endothelial
health must both normalize (or nearly normalize)
vascular function as well as mitigate impairments
in exercise performance as a direct result of the
improvement in both systemic and pulmonary
endothelial function. In the Fontan population,
cardiovascular physiology is altered to such a
degree that improvements in vascular function
Figure 3. Change in peak oxygen consumption among all study subjects. Individual measurements (filled circles) of peak
oxygen consumption (VO2) at baseline and following 1 month of study drug therapy in vitamin C (A) and placebo (B) study
subjects. Treatment with vitamin C for 1 month was not associated with a statistically significant change in peak
VO2 achieved.
Table 4. Reported Side Effects by Treatment Group
Event
Vitamin C Placebo
(n = 27) (n = 26)
Fatigue 1 (4%) 1 (4%)
Headache 1 (4%) 2 (8%)
Rash 0 (0%) 1 (4%)
Decreased appetite 0 (0%) 1 (4%)
Polyuria 1 (4%) 0 (0%)
Any event listed above 3 (11%) 5 (19%)
Values are n (%).
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alone may not drive a corresponding improve-
ment in functional capacity. Recently, we demon-
strated that the two primary factors that play a
role in Fontan exercise intolerance include both
inappropriate elevation in the pulmonary vascular
resistance (or the lack of adequate reduction in
pulmonary vascular resistance that normally
accompanies peak exercise) and diastolic dysfunc-
tion of the systemic ventricle(s).27 As an antioxi-
dant, vitamin C primarily targets oxygen-derived
free radicals (which are elevated in the Fontan
population) resulting in greater NO bioavailabil-
ity, improved endothelial function, and therefore
an increased ability of the pulmonary endothe-
lium to vasodilate in response to exercise.4
However, as was recently demonstrated by Gold-
berg et al., directly targeting the pulmonary vas-
cular bed with oral sildenaﬁl, a phosphodiesterase
type 5 inhibitor with long-standing use in the
treatment of pulmonary hypertension (and an
agent with systemic vascular and direct cardiac
effects in addition to its activity in the pulmonary
vasculature), did not result in substantial
improvements in peak VO2, work, or other key
measures of maximal exercise capacity in a high-
performing Fontan population.9 A signiﬁcant
improvement in ventilatory efﬁciency was attrib-
utable to sildenaﬁl therapy in that study.9 Prior
work from Giardini et al. did demonstrate an
improvement in peak VO2 acutely after adminis-
tration of sildenaﬁl, but the improvement was
clinically marginal and only found in an
extremely low-functioning Fontan population
(VO2 increased from 19.7 to 21.6 mL/kg/min;
both well below the mean VO2 of 30 mL/kg/min
in the present study).28 Therefore, it is reasonable
to surmise that short-term treatment with
sildenaﬁl alone, at least in a reasonably
functional Fontan population, is not enough to
improve exercise capacity in a clinically meaning-
ful way. Longer-term therapy with either vitamin
C or sildenaﬁl, alone or together, or perhaps in
combination with therapy aimed at eliminating
the concomitant burden of ventricular diastolic
dysfunction, may be required to provide a sub-
stantial improvement in exercise function in this
population.
Ascorbic Acid and Endothelial Dysfunction
In the present study, short-term oral vitamin C
therapy was not associated with improvements in
the EndoPAT index and PAT ratio, key markers of
peripheral vascular function, in the cohort overall.
However, in the subgroup of the cohort with
abnormal vascular function at baseline, both the
EndoPAT index and PAT ratio more frequently
normalized in patients receiving vitamin C
therapy, compared with placebo. Although the
study was not powered to evaluate for efﬁcacy of
vitamin C in this relatively small subset of the
cohort, given that this ﬁnding was identiﬁed by a
post hoc analysis, this is arguably the most impor-
tant population to be evaluated. As an antioxidant,
vitamin C therapy would not be expected to
produce measurable improvement in endothelial
function in patients with normal function at base-
line. Rather, if effective, vitamin C ought to nor-
malize (or improve) abnormal vascular endothelial
function. In the absence of available index values
for EndoPAT index and PAT ratio, we chose to
deﬁne the normal range of values in the Fontan
population as those values above the lowest quar-
tile measured in healthy controls of similar age and
sex (these data having been previously ascertained
by our group).7 We felt it likely that the lowest
quartile of healthy control patients contained
most, if not all, of the patients with endothelial
dysfunction and the fewest patients with entirely
normal vascular function. Therefore, we believe
this cutoff to be reasonable. The ﬁndings in our
study are suggestive only, in the absence of a larger
dataset, but they raise the question of whether or
not vitamin C administration in a low-performing
Fontan cohort, with a greater burden of clinical
symptomatology and likely worse vascular health,
would provide a more obvious beneﬁt both to
endothelial function as well as to exercise capacity
and future cardiovascular risk.
Limitations
Our study had several important limitations. The
overall sample size was small and a sizable propor-
tion of patients (17%) failed to complete the study
protocol. This ﬁnding raises concern for possible
underreporting of side effects. Moreover, the small
study population is underpowered to properly
evaluate subgroups within the cohorts, thereby
eliminating our ability to identify differences in
characteristics of vitamin C responders and non-
responders. Study recruitment focused on the
high-performing, generally asymptomatic Fontan
patients, which limited our ability to generalize
the study ﬁndings to a Fontan patient with a
greater degree of functional impairment. Future
study is needed to better address the degree of
endothelial dysfunction, and impact of directed
therapy, in a low-performing Fontan cohort.
Peripheral arterial tonometry testing measures
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peripheral (digital) vascular function and corre-
lates closely with, but is not identical to, brachial
artery ﬂow-mediated vasodilation testing (see our
groups’ recent report for a full discussion of the
technical considerations and physiology of PAT
testing in the Fontan population7).16 Additionally,
the vitamin C course in this study was limited to 4
weeks, thereby preventing an evaluation of the
long-term efﬁcacy and side-effect proﬁle of this
medication in a Fontan population.
Conclusions
While antioxidants such as vitamin C are compel-
ling candidate medications from a mechanistic
standpoint, it is unclear what therapeutic role they
may have to play in the Fontan population. There
is a suggestion that vitamin C may improve vascu-
lar function in the subpopulation of Fontan
subjects with baseline evidence of endothelial dys-
function. Further study in a broader spectrum of
the Fontan population and for a longer duration is
necessary prior to determining the ultimate role of
antioxidant therapy in the long-term treatment of
the palliated single-ventricle patient.
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